Valuation: ProSomnus, Inc.

Market Cap 237K 208K 191K 179K 336K 22.32M 342K 2.3M 890K 11M 888K 869K 38.24M P/E 2022
-7.8x
P/E 2023 -0.66x
Enterprise Value 35.24M 30.96M 28.52M 26.67M 50.02M 3.33B 50.94M 342M 133M 1.64B 132M 129M 5.7B EV / Sales 2022
5.49x
EV / Sales 2023 1.85x
Free-Float
90.18%
Yield 2022 *
-
Yield 2023 -
3 years 0
Extreme 0.004
3.95
5 years 0
Extreme 0.004
11.3
10 years 0
Extreme 0.004
11.3
Manager TitleAgeSince
Chief Executive Officer 52 2022-05-02
Chief Tech/Sci/R&D Officer 45 2022-05-02
Director of Finance/CFO 57 2023-02-28
Date Insider Type Main position Quantity % Market Cap.
24-02-14Free

Chief Executive Officer

1,322,756 8.0663%
24-02-14Free

Founder

315,742 1.9254%
24-02-14Free

Chief Financial Officer

315,742 1.9254%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-99.66% 237K
+3.13%+10.84%-23.42%+17.27% 3.81B
+2.26%+13.30%+27.71% - 1.32B
+6.02%+9.43%+2.12% - 749M
-5.95%-16.37%+92.68%+105.02% 142M
+4.69%0.00%+1.13%-24.29% 152M
-3.53%-18.41%+86.41%+14.69% 74.22M
-53.44%+46.01%-11.56%-71.91% 33.49M
Average -5.85%+6.88%+21.88%-9.81% 785.09M
Weighted average by Cap. +2.74%+10.28%-5.07%+17.96%

Financials

2022 2023
Net sales 19.39M 17.04M 15.7M 14.68M 27.52M 1.83B 28.03M 188M 72.94M 902M 72.83M 71.23M 3.13B 27.65M 24.29M 22.38M 20.92M 39.25M 2.61B 39.97M 269M 104M 1.29B 104M 102M 4.47B
Net income -7.15M -6.28M -5.78M -5.41M -10.14M -674M -10.33M -69.38M -26.87M -332M -26.83M -26.24M -1.16B -24.1M -21.17M -19.5M -18.23M -34.2M -2.27B -34.82M -234M -90.62M -1.12B -90.48M -88.5M -3.89B
Net Debt 17.17M 15.08M 13.89M 12.99M 24.36M 1.62B 24.81M 167M 64.56M 798M 64.46M 63.05M 2.77B 35.01M 30.75M 28.33M 26.49M 49.68M 3.3B 50.59M 340M 132M 1.63B 131M 129M 5.66B
Logo ProSomnus, Inc.
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
Employees
136
  1. Stock Market
  2. Stocks
  3. LAAA Stock